Read by QxMD icon Read

Urology cancer

Shingo Fukuma, Miho Kimachi, Kenji Omae, Yuki Kataoka, Hajime Yamazaki, Manabu Muto, Tadao Akizawa, Motoko Yanagita, Shunichi Fukuhara
BACKGROUND: Although cancer management in dialysis patients has become a commonly encountered issue, known as "onco-nephrology", few evidence-based clinical recommendations have been proposed. Here, we examined the variation in referral behaviors adopted by dialysis physicians on encountering dialysis patients with signs/symptoms suggestive of cancer. METHODS: We conducted a vignette-based study in August 2015. We sent a 14-page questionnaire to 191 dialysis physicians, including the representative dialysis facilities participating in a Japanese dialysis cohort (the Japan Dialysis Outcomes and Practice Patterns Study)...
2018: PloS One
Mario I Fernández, Maurizio Brausi, Peter E Clark, Michael S Cookson, H Barton Grossman, Makarand Khochikar, Lambertus A Kiemeney, Bernard Malavaud, Rafael Sanchez-Salas, Mark S Soloway, Robert S Svatek, Raghunandan Vikram, Alina Vrieling, Ashish M Kamat
PURPOSE: To update current recommendations on prevention, screening, diagnosis, and evaluation of bladder cancer (BC) based on a thorough assessment of the most recent literature on these topics. METHODS: A non-systematic review was performed, including articles until June 2017. A variety of original articles, reviews, and editorials were selected according to their epidemiologic, demographic, and clinical relevance. Assessment of the level of evidence and grade of recommendations was performed according to the International Consultation on Urological Diseases grading system...
August 13, 2018: World Journal of Urology
Marlon Perera, Shannon McGrath, Shomik Sengupta, Jack Crozier, Damien Bolton, Nathan Lawrentschuk
Radical cystectomy is the gold-standard treatment option for muscle-invasive and metastatic bladder cancer. At the time of cystectomy, up to 25% of patients harbour metastatic lymph node deposits. These deposits most frequently occur in the obturator fossa, but can be as proximal as the interaortocaval region. Thus, the use of concurrent pelvic lymph node dissection (PLND) with cystectomy has been increasingly reported. Data from studies including many patients suggest substantial oncological benefit in PLND cohorts versus non-PLND cohorts, irrespective of pathological nodal status...
August 13, 2018: Nature Reviews. Urology
Isabel Rauscher, Matthias Eiber, Wolfgang A Weber, Jürgen E Gschwend, Thomas Horn, Tobias Maurer
Positron-emission tomography/computed tomography combining both functional and morphological information has emerged as a powerful tool in oncological imaging within the past decades. The most commonly used radiotracer in oncology visualizing metabolic information is 2-[18F]fluoro-2-deoxy-d-glucose. However, the use of 2-[18F]fluoro-2-deoxy-d-glucose in urological oncology is challenging, as it is limited by physiological excretion through the urinary system. Therefore, it is only useful when applied to specific indications in selected patients with urological malignancy; for example, for detection of residual disease in the post-chemotherapy management of patients with seminoma...
August 13, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
Marco Bandini, Nicola Fossati, Alberto Briganti
PURPOSE OF REVIEW: To critically review the current literature regarding the recently published nomograms in urologic oncology and to examine the advantages and disadvantages of their application. RECENT FINDINGS: Several nomograms have been developed in the field of urologic oncology over the recent years, to improve clinical decision-making and patients counseling. In the current review, we examined 6 nomograms on prostate cancer, 9 nomograms on kidney cancer and 8 nomograms on bladder cancer that have been recently published...
August 7, 2018: Current Opinion in Urology
Anna Patrikidou, Pierre Maroun, Jean-Jacques Patard, Hervé Baumert, Laurence Albiges, Christophe Massard, Yohann Loriot, Bernard Escudier, Mario Di Palma, Julia Arfi-Rouche, Laurence Rocher, Zahira Merabet, Alberto Bossi, Karim Fizazi, Pierre Blanchard
Objectives: The initial treatment decision for newly diagnosed non-metastatic prostate cancer is complex. Multiple valid approaches exist, without a clear and absolute consensus for every clinical scenario, and therefore specialist opinions may vary. Multidisciplinary consultations focusing on shared decision-making aim to provide an apposite tool for the initial treatment decision. We have evaluated the first two years of activity of the Gustave Roussy Prostate Cancer Multidisciplinary Clinic (PCMC), dedicated to the initial decision-making for non-metastatic prostate cancer...
August 2018: Clinical and Translational Radiation Oncology
Juan Li, Zhigang Cui, Hang Li, Xiaoting Lv, Min Gao, Zitai Yang, Yanhong Bi, Ziwei Zhang, Shengli Wang, Baosen Zhou, Zhihua Yin
Background: The aberrant regulation of MALAT1 has been indicated to be involved in various carcinogenic pathways contributing to the tumourigenesis and progression of cancers. The current meta-analysis summarized the research advances of MALAT1 functions and analyzed its prognostic value among multiple types of cancers. Methods: Eligible studies were identified through retrieving the PubMed, Web of Science, and CNKI databases, up to Mar 1, 2018. 28 studies of 5436 patients and 36 studies of 3325 patients were enrolled in the meta-analysis to evaluate the association of MALAT1 expression with survival outcomes and clinical parameters...
2018: Cancer Cell International
Simone Scarcella, Lucio Dell'Atti, Andrea Benedetto Galosi
The most common malignancy in young men is a germ cell tumour of the testes. Metastatic renal disease is relatively uncommon and usually manifests in the retroperitoneal lymph nodes. Visceral metastases to the liver, and metastases to the lungs and the brain are more common. Few large studies characterising patients with germ cell tumours and associated renal metastases have yet been published. We report an unusual case of successful management, through demolitive surgery, of a 22-year-old male patient affected by spontaneous intrarenal rupture of metastases secondary to testicular cancer...
August 9, 2018: BMJ Case Reports
Hideto Ueki, Takuya Fujimoto, Masato Okuno, Yuji Kusuda, Isao Taguchi, Yasushi Itou, Sawami Kiyonaka, Gaku Kawabata
Background: CT-guided marking technique is rarely used in abdominal or urologic surgery. We developed and performed a marking technique for a small tumor, undetectable by ultrasound, using CT guidance before laparoscopic resection of the tumor. Case Presentation: A 73-year-old woman with a history of breast cancer underwent right colectomy with D3 lymph node dissection for ascending colon cancer. Five years after the operation, a solitary tumor was found in the right pararenal region of the retroperitoneal space on enhanced abdominal CT...
2018: Journal of Endourology Case Reports
A Juárez-Soto, J M Garín-Ferreira, A Rodríguez-Fernández, J L Tirado-Hospital, M T González-Serrano, J Moreno-Jiménez, R Medina-López, V Baena-González
INTRODUCTION: In castration-resistant prostate cancer (CRPC), early detection of metastases is essential for the selection of treatment, and prevention of bone complications. However detecting incipient metastases remains a challenge as the conventional radiological tests (bone scintigraphy or computerised tomography) lack sufficient sensitivity. Diagnostic imaging techniques are currently available that have greater sensitivity and specificity, but are little used due to shortfalls in the recommendations...
August 3, 2018: Actas Urologicas Españolas
Joel E Pacyna, Simon Kim, Kathleen Yost, Hillary Sedlacek, Daniel Petereit, Judith Kaur, Bruce Rapkin, Robert Grubb, Electra Paskett, George J Chang, Jeff Sloan, Ethan Basch, Brittny Major, Paul Novotny, John Taylor, Jan Buckner, J Kellogg Parsons, Michael Morris, Jon C Tilburt
BACKGROUND: Treatments for localized prostate cancer present challenging tradeoffs in the face of uncertain treatment benefits. These options are best weighed in a process of shared decision-making with the patient's healthcare team. Minority men experience disparities in prostate cancer outcomes, possibly due in part to a lack of optimal communication during treatment selection. Decision aids facilitate shared decision-making, improve knowledge of treatment options, may increase satisfaction with treatment choice, and likely facilitate long-term quality of life...
August 6, 2018: BMC Cancer
Judith Bosschieter, Jakko A Nieuwenhuijzen, André N Vis, Tessa van Ginkel, Birgit I Lissenberg-Witte, Goedele M A Beckers, R Jeroen A van Moorselaar
BACKGROUND: In a recent meta-analysis, subgroups of patients were defined that may not benefit from a single, immediate instillation with chemotherapy. This led to a change in the European Association of Urology bladder cancer guidelines. In a previous paper, our group confirmed the efficacy of an immediate instillation of mitomycin C (MMC). However, prognostic groups in that study differ from those in the meta-analysis. Therefore, we performed a reanalysis using contemporary risk groups...
July 28, 2018: Urologic Oncology
U Jayarajah, K B Herath, M H Fernando, S N Kuruppu, U L Wickramanayaka, I U Fernando, D S Lokuhetty, V C de Silva, S A S Goonewardena
No abstract text is available yet for this article.
June 30, 2018: Ceylon Medical Journal
Richard J Fantus, Andrew Cohen, Christopher B Riedinger, Kristine Kuchta, Chi H Wang, Katharine Yao, Sangtae Park
To evaluate trends in contemporary robotic surgery across multiple organ sites as they relate to robotic prostatectomy volume. We queried the National Cancer Database for patients who underwent surgery from 2010 to 2013 for prostate, kidney, bladder, corpus uteri, uterus, cervix, colon, sigmoid, rectum, lung and bronchus. The trend between volumes of robotic surgery for each organ site was analyzed using the Cochran-Armitage test. Multivariable models were then created to determine independent predictors of robotic surgery within each organ site by calculating the odds ratio with 95% CI...
July 30, 2018: Journal of Robotic Surgery
Mareike K Thompson, Philip Poortmans, Anthony J Chalmers, Corinne Faivre-Finn, Emma Hall, Robert A Huddart, Yolande Lievens, David Sebag-Montefiore, Charlotte E Coles
As we mark 150 years since the birth of Marie Curie, we reflect on the global advances made in radiation oncology and the current status of radiation therapy (RT) research. Large-scale international RT clinical trials have been fundamental in driving evidence-based change and have served to improve cancer management and to reduce side effects. Radiation therapy trials have also improved practice by increasing quality assurance and consistency in treatment protocols across multiple centres. This review summarises some of the key RT practice-changing clinical trials over the last two decades, in four common cancer sites for which RT is a crucial component of curative treatment: breast, lung, urological and lower gastro-intestinal cancer...
July 31, 2018: British Journal of Cancer
Marko Babjuk, Maximilian Burger, Eva M Compérat, Paolo Gontero, Hugh A Mostafid, Joan Palou, Bas W G van Rhijn, Morgan Rouprêt, Shahrokh F Shariat, Richard Sylvester, Richard Zigeuner, Otakar Capoun, Daniel Cohen, José L Dominguez-Escrig, Virginia Hernández, Benoit Peyronnet, Thomas Seisen, Viktor Soukup
An early single instillation of intravesical chemotherapy (SICI) used immediately after transurethral resection of the bladder (TURB) can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer (NMIBC). SICI should be used in patients with low-risk and with selected intermediate-risk tumours, in particular for multiple primary small papillary tumours, single primary papillary tumours >3cm, and single recurrent papillary tumours recurring >1yr after the previous resection...
July 27, 2018: European Urology Focus
Shoji Kimura, Francesco Soria, David D'Andrea, Beat Foerster, Mohammad Abufaraj, Mihai D Vartolomei, Pierre I Karakiewicz, Romain Mathieu, Marco Moschini, Michael Rink, Shin Egawa, Shahrokh F Shariat, Kilian M Gust
BACKGROUND: Serum cholinesterase (ChE) has been reported to be a prognostic factor in several cancers, but its relationship with oncologic outcomes of non-muscle-invasive bladder cancer (NMIBC) has not yet been well-studied. MATERIALS AND METHODS: We retrospectively assessed 1117 patients with NMIBC undergoing transurethral resection of the bladder. Cox regression analyses were performed to elucidate the association between preoperative ChE and oncologic outcomes such as recurrence-free survival (RFS) and progression-free survival...
July 6, 2018: Clinical Genitourinary Cancer
Levent Isikay, Senol Tonyali, Gulden Aydog
PURPOSE: To determine if there is a correlation between the newly proposed Gleason grading system by the International Society of Urological Pathology and the Cancer of the Prostate Risk Assessment (CAPRA) score. MATERIAL AND METHODS: The records of all patients that underwent radical prostatectomy at our hospital between 2007 and 2013 were retrospectively reviewed. The study parameters included patient demographics, the percentage of pre-operative prostate biopsies positive for PCa, biopsy Gleason Score (GS), and pre- and post-operative PSA values...
July 30, 2018: Urology Journal
Mehrzad Lotfi, Reza Beheshti, Mohammad Reza Rouhezamin, Abbas Rezaianzadeh, Pouya Farhadi, Zeinab Daneshi
Background: Prostate cancer is the most common malignancy among the male population in the United States and the 3rd most common non-skin cancer among men in Iran. Its prevalence has shown a rising trend in recent decades. The aim of this study was to report the epidemiological features of prostate cancer in patients referred for prostate biopsy in the south of Iran and to evaluate the accuracy of the levels of the prostate-specific antigen (PSA) and the PSA-density (PSAD) as well as the extension of the disease in the prediction of the biological behavior of prostate cancer...
July 2018: Iranian Journal of Medical Sciences
Tiffany M Morgan, Robert H Press, Patrick K Cutrell, Chao Zhang, Zhengjia Chen, Sara Rahnema, Jaymin Jhaveri, Martin Sanda, John Pattaras, Pretesh Patel, Ashesh B Jani, Peter J Rossi
Purpose: There is limited data to support the use of hypofractionated external beam radiation (HypoF) in combination with high-dose-rate brachytherapy (HDR). We report our quality of life (QOL) outcomes when treating intermediate and high-risk prostate cancer patients with external beam radiation (EBRT) plus HDR. Material and methods: The charts of 54 patients with localized adenocarcinoma of the prostate treated with standard fractionation (SF) or HypoF EBRT plus HDR boost at a single institution between 2012 and 2015 were reviewed...
June 2018: Journal of Contemporary Brachytherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"